I V Maev
Overview
Explore the profile of I V Maev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
235
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maev I, Yurenev G, Barkalova E, Ovsepian M, Andreev D, Shaburov R
Ter Arkh
. 2024 Oct;
96(8):757-763.
PMID: 39404720
Aim: To determine the phenotypic variants of patients with symptoms of gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), hypersensitive esophagus (HSE), functional heartburn (FH) using 24-hour pH-impedance testing and...
2.
Andreev D, Maev I, Bordin D, Abdulkhakov S, Shaburov R, Sokolov P
Ter Arkh
. 2024 Oct;
96(8):751-756.
PMID: 39404719
Aim: To systematize data on the prevalence of gastroesophageal reflux disease (GERD) in the adult population of Russia. Materials And Methods: The search for studies was conducted in the electronic...
3.
Maev I, Velikolug K
Ter Arkh
. 2024 Oct;
96(8):723-731.
PMID: 39404715
Aim: To highlight the relevance of gastrointestinal manifestations of cytomegalovirus infection (CMVI), to highlight the main risk factors for the development of this pathology, current trends in diagnosis and treatment....
4.
Yanushevich O, Maev I, Krikheli N, Levchenko O, Galeeva J, Starikova E, et al.
Ter Arkh
. 2024 May;
95(12):1103-1111.
PMID: 38785049
Aim: To study overall drug resistance genes (resistome) in the human gut microbiome and the changes in these genes during COVID-19 in-hospital therapy. Materials And Methods: A single-center retrospective cohort...
5.
Maev I, Osadchuk M
Ter Arkh
. 2023 Dec;
95(7):586-590.
PMID: 38159010
A significant prevalence of gastrointestinal symptoms in SARS-CoV-2 infection is also associated with its fecal-oral transmission, which leads to a progressive increase in the number of patients with diseases of...
6.
Maev I, Bakulin I, Skalinskaya M, Skazyvaeva E
Ter Arkh
. 2023 Dec;
95(12):1064-1074.
PMID: 38158940
The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing...
7.
Maev I, Andreev D, Zaborovsky A, Lobanova E
Ter Arkh
. 2023 Dec;
95(8):716-721.
PMID: 38158912
Acotiamide is a prokinetic with a novel mechanism of action - an antagonist of muscarinic M and M receptors and an acetylcholinesterase inhibitor. Acetylcholine is the central mediator of the...
8.
Dudina K, Belyy P, Maev I, Klimova E, Shutko S, Znoyko O, et al.
Ter Arkh
. 2023 Dec;
95(8):634-640.
PMID: 38158898
Aim: To evaluate the body mass index (BMI) in patients with chronic hepatitis C (CHC) with different stages of liver fibrosis and steatosis who received effective antiviral therapy (AVT). Materials...
9.
Maev I, Polunina T
Ter Arkh
. 2023 Dec;
95(8):611-620.
PMID: 38158894
Drug-induced liver injury (DILI) is a relevant issue in clinical practice and is still a diagnosis of exclusion. Despite the low incidence in the general population, DILI is the cause...
10.
Maev I, Shaburov R, Pavlov A, Molodova A, Karakozov A, Kazakov S, et al.
Ter Arkh
. 2023 May;
94(12):1413-1420.
PMID: 37167187
Background: The article reflects the clinical significance of the early diagnosis of toxic hepatitis in patients who have undergone a new coronavirus infection with the determination of clinical and laboratory...